The present disclosure relates to a method for prevention and/or treatment of a disease or disorder mediated by NLRP3 in a subject, comprising administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or prodrug as disclosed herein

##STR00001##

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

The present application relates to a benzo five-membered nitrogen heterocyclic compound and an application thereof. The benzo five-membered nitrogen heterocyclic compound has the structure represented by formula I. The compound can be used as a compound of RORγ receptor inhibitor. The compound can effectively inhibit RORγ proteins and have good selectivity to other nuclear receptor family proteins. The benzo five-membered nitrogen heterocyclic compound or a pharmaceutical composition thereof provided by the present application can be used for preparing a drug for treating, preventing or ameliorating diseases such as inflammations, autoimmune diseases, cell proliferative disorder diseases, sepsis, cancer, neurodegeneration diseases or viral infections, has a good inhibitory effect on the treatment of tumors, especially the treatment of prostate cancer, and also has an amelioration effect on the treatment of other diseases.

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. ##STR00001##

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. ##STR00001##

Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.

Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.

Disclosed herein is the use of a first population of allogeneic T-cells recognizing a first EBV epitope, and a second allogeneic population recognizing a second EBV epitope in the treatment of EBV-associated disorders. Also disclosed is the use of a population of allogeneic T-cells recognizing an EBV antigen in combination with a further therapeutic agent such as an immunotherapeutic agent, a MAPK, BET or MEK. pathway inhibitor for treating EBV-associated disease.